TP53 Mutations in EGFR-Mutant and Risk Stratification

TP53 mutations occur in over 50% of patients with EGFR-mutant lung cancer, representing a consistently negative prognostic factor. Dr. Rotow explains that TP53 mutations appear prominently on NGS reports, requiring clinicians to determine appropriate management strategies.

Historical recognition of TP53 as an adverse prognostic factor lacked actionable interventions until frontline combinations became available. TP53 mutations often occur without other classical high-risk features, creating decision-making challenges about treatment intensification.

Subgroup analyses from both FLAURA-2 and MARIPOSA suggest benefits for intensification in TP53-mutant patients, with stronger quality evidence from MARIPOSA due to pre-specified risk factor analysis. FLAURA-2 showed similar trends but with less robust data due to post-hoc analysis design.

Dr. Lopes presents data from the TROP study, which prospectively examined patients with EGFR mutations and TP53 co-mutations. The study demonstrated median PFS improvement from 15 to 16 months to over 34 months with chemotherapy intensification. A parallel Chinese study using aumolertinib showed similar doubling of median PFS by adding chemotherapy to patients with tumor suppressor gene mutations.

Although these studies confirm benefits for intensification in TP53-mutant patients, Dr. Lopes emphasizes that patients without TP53 mutations also derive intensification benefits. Therefore, TP53 status represents additional supportive data rather than a definitive decision-making factor.

Dr. Camidge notes that TP53 mutations enrich for high-risk populations without guaranteeing poor outcomes, as many TP53-mutant patients achieve excellent responses on osimertinib monotherapy.